The critical role of a CRO to navigate rare disease and orphan drug development

Your product's success depends on optimizing the treatment journey. Learn how a robust strategy can address the obstacles that patients and healthcare providers face and strengthen each patient connection.

Learn how a robust reimbursement program is critical to launching a successful biosimilar product.

Inclusion/Exclusion Criteria: A Case Study

Learn how in-depth collaboration during a complex program help sped the development process, saving time and money.

ACCP 2016 -- The prostacyclin analogue beraprost (BPS) consists of a mixture of 4 stereoisomers and is available for treatment of PAH in Japan and other Asian countries.

ACCP 2016 -- The prostacyclin analogue beraprost (BPS) consists of a mixture of 4 stereoisomers and is available for treatment of PAH in Japan and other Asian countries.

ICCS 2016 -- Plasmablasts and plasma cells are antibody-producing cells that are implicated in the pathogenesis of autoantibody-driven immune diseases. Plasmablasts are terminally differentiating B cells that are rapidly produced with the majority becoming short-lived effector cells and the minority becoming long-lived plasma cells.

GlycoMimetics, Inc. and MI Bioresearch Poster for SITC